A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874
- Conditions
- Moderate to severe chronic plaque psoriasisMedDRA version: 13.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
- Registration Number
- EUCTR2007-005955-40-DK
- Lead Sponsor
- Abbott GmbH & Co. K.G.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
? Having participated in a preceding ABT-874 clinical trial for ABT-874
? Subject has a clinical diagnosis of moderate to severe plaque psoriasis
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
?Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method